Event

Why are ADHD diagnoses rising among adults? What’s driving GLP-1 discontinuation despite its transformative potential? Why do some patients remain on injectable HIV prevention while others abandon it? Real-world evidence is revealing surprising trends and critical gaps in diagnosis, prescribing, and adherence. In this exclusive webinar, Truveta researchers will share key insights from four new studies presented at ISPOR 2025, demonstrating how Truveta Data can uncover real-world practice patterns for high-profile therapies faster than any clinical trial or registry.

Learning Objectives

• Shifting treatment patterns: How FDA approval of GLP-1 Receptor Agonists for cardiovascular disease influenced prescribing trends – and why use may already be declining.
• Drivers of discontinuation: Why patients stop GLP-1 therapy and how reasons differ between obesity and diabetes treatment.
• Adherence challenges in HIV care: What real-world data reveals about who stays on injectable cabotegravir and who drops off treatment.
• New trends in ADHD diagnosis and treatment: Which demographics are experiencing a rise in ADHD diagnoses and amphetamine prescribing.

Why Truveta Data? 
Truveta Data is the most representative, complete, and timely patient journey data, exceeding FDA standards for data quality, provenance, and audit readiness. Researchers can analyze de-identified EHR data from over 120 million patients, including more than 7 billion clinical notes and 100 million medical images – across all care settings.